Pharma

  • Arun Krishna, AstraZeneca
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip
    Q&A

    Inside AstraZeneca’s long-term strategy in lung cancer

    Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.

    By Michael Gibney • Aug. 8, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Elevidys sales weaken; Neumora gets into obesity

    Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

    By BioPharma Dive staff • Aug. 8, 2025
  • A stylized illustration of a pill breaking apart into smaller pills. Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Trendline

    Top 5 stories from BioPharma Dive

    Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

    By BioPharma Dive staff
  • Eli Lilly company logo outside its Indiana headquarters
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly shares fall as obesity pill misses expectations in key trial

    While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a selloff in shares that erased about $100 billion in market value. 

    By • Aug. 7, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo pushes back against obesity drug compounders as competition intensifies

    The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

    By • Aug. 6, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share

    The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled sales numbers for their chief drugs.

    By BioPharma Dive staff • Aug. 6, 2025
  • Pfizer CEO Albert Bourla
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip
    Emerging biotech

    US biotech needs government support to match China’s gains, Pfizer CEO says

    “The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in comments on China’s rising competitiveness.

    By • Aug. 5, 2025
  • A Pfizer sign sits outside the company's Ian C. Read Laboratories in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO

    Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to-consumer options.

    By • Aug. 5, 2025
  • President Donald Trump speaks to reporters at the the Lehigh Valley International Airport on Aug. 3, 2025, in Allentown, Pennsylvania.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Trump threatens up to 250% tariffs on pharma imports

    The president said he would first install a “small tariff” on pharmaceutical goods before ratcheting up the rate over the next year and a half.

    By Philip Neuffer • Aug. 5, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Regeneron cancer bispecific rejected again; Allogene discloses trial death

    The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

    By BioPharma Dive staff • Aug. 1, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval

    Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.

    By • July 30, 2025
  • A low stone wall partially obscured by long grass bears a Merck & Co. logo
    Image attribution tooltip
    Jason Doiy via Getty Images
    Image attribution tooltip

    Merck plans spending shift to boost business beyond Keytruda

    Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support of newer drugs and R&D.

    By • July 29, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Novo cuts guidance, names new CEO as obesity drug challenges mount

    Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its competition with rival Eli Lilly.

    By • July 29, 2025
  • A photo of a building showing a GSK sign in London.
    Image attribution tooltip
    Courtesy of GSK
    Image attribution tooltip

    GSK pays $500M to enter drugmaking alliance with Hengrui

    The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines and be worth $12 billion.

    By • July 28, 2025
  • Art
    Image attribution tooltip
    Permission granted by PHIL
    Image attribution tooltip
    Sponsored by PHIL

    Redefining commercial success in specialty lite with alternative channels

    The optimal commercial strategy for specialty-lite brands – alternative channels to drive unparalleled commercial outcomes.

    July 28, 2025
  • The Bayer logo hangs on the side of a building.
    Image attribution tooltip
    Maja Hitij via Getty Images
    Image attribution tooltip

    FDA delays approval decision for Bayer menopause therapy

    The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and the U.K. have already cleared it for use.

    By • July 25, 2025
  • A sign spelling Bristol Myers Squibb hangs on the side of an office building.
    Image attribution tooltip
    JHVEPhoto via Getty Images
    Image attribution tooltip

    Bristol Myers shuffles its executive ranks with new CMO

    AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit Hirawat, on Aug. 1.

    By • July 25, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Rocket lays off staff; Abivax capitalizes on immune drug data

    The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

    By BioPharma Dive staff • July 24, 2025
  • Close-up of a building with a purple and yellow AstraZeneca sign on the exterior.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial

    The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells for myasthenia gravis.

    By • July 24, 2025
  • This image depicts the podcast series cover image for Pearson's BioPharma Dive series, "The Progress Profile: Alzheimer’s Research in Focus"
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] The Progress Profile: Alzheimer’s Research in Focus

    Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

    By BioPharma Dive's studioID • July 24, 2025
  • A sign spelling Roche hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip

    Roche stops shipping Sarepta gene therapy in some countries outside US

    The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in Duchenne patients who can still walk, however.

    By • July 23, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Replimune drug rejected by FDA; Omega raises $647M biotech fund

    Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

    By BioPharma Dive staff • July 22, 2025
  • A person in a dark business suit speaks at a podium in front of U.S. and Virginia flags.
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip

    AstraZeneca grows US presence with $50B in spending plans

    The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.

    By • July 21, 2025
  • Basket of apples
    Image attribution tooltip

    Adobe Stock/Alexander

    Image attribution tooltip
    Sponsored by MMIT, a Norstella company

    Apples to apples: Stelara biosimilars and the fight for market share

    How will payers determine which Stelara biosimilar to add to their formularies?

    By Samantha Ngan, Associate Manager, Market Research, MMIT and Andrew Rouff, Senior Consultant, Advisory Services, MMIT • July 21, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel

    The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.

    By BioPharma Dive staff • July 18, 2025
  • A photo of Bristol Myers Squibb and Pfizer's anticoagulant drug Eliquis
    Image attribution tooltip
    Scott Olson / Staff via Getty Images
    Image attribution tooltip

    Bristol Myers, Pfizer to offer Eliquis at a discount for some patients

    The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who aren’t insured or are willing to pay cash for their medications. 

    By • July 17, 2025